15/12/2010
ReGen Signs Agreement with Framingham Pharma for the potential Distribution of its Nutraceutical ColostrininTM in Argentina, Uruguay and Paraguay.
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company) announces that it has today signed a Material Transfer Agreement (MTA) with Framingham Pharma of Argentina.
Framingham is the leading marketer of dietary supplements in Argentina. The second largest market in South America, which is a growth area of the world economy. Framingham reaches consumers across Argentina with a presence in all pharmacies. It promotes its products through direct contact with health professionals, participation in scientific events and significant media activity. Framingham is a prestigious laboratory recognized by both health professionals and the general public in Argentina. Framingham also has a significant distribution capability in Uruguay and Paraguay with local partners.
Additional information is available on its corporate website www.framinghampharma.com
Under the terms of this agreement ReGen will provide sufficient quantity of its proprietary nutraceutical ingredient Colostrinin(TM) to allow Framingham to develop a local formulation, initially for marketing in Argentina. If successful this exercise will lead to the signing of a formal Licensing and Distribution Agreement between the parties making Framingham the exclusive distributor of Colostrinin(TM) in Argentina and other markets in the region.
No further details of the agreement will be disclosed at this time.
To date Colostrinin(TM) is marketed as a nutritional supplement to ‘support healthy brain aging and cognition in humans’ in the US, Canada, Australia and Poland under the brand name CogniSure(TM) *, in Cyprus under the brand name Cognase(TM) **, in the UK under the brand name MemoryAid (TM) ***, in Turkey under the brand name Dyna(TM) **** and in India under the brand name Cognate (TM) *****
LG Life Sciences, Ltd (‘LGLS’) have also been appointed as the exclusive distributor of ColostrininTM in South Korea subject to import and regulatory approval being obtained******.
Following on from India, Turkey and S Korea the ReGen Board is delighted that the Company has entered yet another growing market, which should lead to growth in sales higher than in the older developed world.
* Colostrinin(TM) for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.metagenics.com).
Colostrinin(TM) is distributed in Poland by Tagerr Polska, an affliate of Tagerr a professional services and trading company established in Köln, Germany. (www.cognisure.eu)
** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi Pharmaceuticals Ltd (www.healthybrainaging.com).
*** Colostrinin(TM) is distributed in the UK by PRG Nutraceuticals Ltd (www.memoryaid.com)
**** Colostrinin(TM) is distributed in Turkey by Eczacibasi Ilac Pazarlama A.S (www.eczacibasi.com)
***** Colostrinin(TM) is distributed in India by USV Ltd (www.usvindia.com )
****** LG Life Sciences, South Korea (www.lgls.co.kr)
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820